AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
UbiVac’s Commitment to Cancer Treatment
UbiVac’s mission is to develop next-generation immunotherapies like DPV-001 that generate broad, multi-targeted immune responses—including against Dark Genome-derived cancer’s “Dark Matter”—to reduce tumor escape and drive durable clinical benefit.
Targeting Cancer’s Dark Genome: First Vaccine-Induced TCR Against Dark Matter Antigen
UbiVac’s lead clinical-stage immunotherapy, DPV-001, was first evaluated as adjuvant therapy for non-small cell lung cancer in an NCI-funded trial. At AAI 2025, UbiVac presented a landmark finding from that study:
1. A Dark Matter antigen—derived from the non-coding, or “dark,” genome—was identified in the patient’s tumor.
2. DPV-001 contained this specific dark matter antigen and induced, in the patient, a tumor-destructive T cell receptor (TCR) against it.
3. The TCR response occurred without adverse events, suggesting selectivity for cancer cells and sparing of normal tissue.
4. The patient remains alive and disease-free 10 years post-treatment.
UbiVac believes this represents the first documented case of a vaccine-induced TCR targeting a Dark Genome-derived Dark Matter antigen—offering compelling evidence of both cancer specificity and safety.
About Cancer’s Dark Matter
Cancer’s dark matter represents a spectrum of previously unknown proteins that have recently been identified as antigens expressed on the surface of cancer cells but not on normal cells or the thymus. Some of these dark matter proteins appear to be responsible for cancer’s malignant properties, making them valuable targets for an anti-cancer immune response. UbiVac believes DPV-001 is the first cancer immunotherapy to include cancer’s dark matter in a form that can induce a destructive anti-cancer immune response and established its therapeutic efficacy in more than a decade’ worth of preclinical studies.
About DPV-001
UbiVac’s DRibble Platform Vaccine (DPV) technology is a novel first-in-class cancer vaccine immunotherapy that has tripled response rates in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). DPV-001 was developed to be used as combination immunotherapy for most solid cancers, including cancers of the breast, lung, prostate, stomach, colon, pancreas, ovary, brain, and others. DPV-001 contains recently described non-canonical, non-mutated shared alternative neoantigens, also termed cancer’s “dark matter”, plus more than 300 antigens overexpressed by the average solid cancer. This allows DPV-001 to be available off-the-shelf without having to manufacture a patient specific vaccine. Additionally, DPV-001 can be administered without having to match a patients HLA tissue antigens.
About Lung Cancer
Lung cancer is the leading cause of cancer death in the USA and worldwide, accounting for about 1 in 5 of all cancer deaths annually. The American Cancer Society estimates that each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. UbiVac believes the early data presented here, as well as previous data showing DPV-001 contains several hundread antigens present in the majority of human cancers, including cancers of the lung, prostate, breast, brain, pancreas, stomach, ovaries, bladder, suggests that DPV-001 can provide a trigger to induce cancer destructive immune responses and increase the efficacy of checkpoint blockade or chemotherapy.
About UbiVac
UbiVac is a privately held, Clinical Stage Immunotherapy & Cancer Target Discovery Company, with First-in-Human Combination Immunotherapies that Include Cancer’s Dark Matter - the Newly Discovered Non-Mutated Shared Alternative Cancer Neoantigens derived from the dark genome. UbiVac is actively looking for partners to accelerate development of this disruptive technology.
DPV-001 is UbiVac’s lead agent and is a first-in-class platform technology that couples an off-the-shelf DC-targeted microvesicle containing cancer’s dark matter plus more than 300 cancer antigens for most adenocarcinomas and squamous cell cancers. DPV-001 also contains multiple TLR/NOD agonists and DAMPs that are effective at supporting anti-cancer immune responses. UbiVac believes that DPV-001 is highly complementary to current and developing immunotherapy, adoptive immunotherapy, chemotherapy and small molecule drug portfolios, and preliminary clinical data suggests it may be effective at increasing response rates in patients that have failed to respond to anti-PD-1/anti-PD-L1. UbiVac also has a pipeline of agents under development for the treatment of melanoma and thyroid cancer, and to prevent cancer in patients at high risk of developing disease.
Bernard A Fox
UbiVac
+1 971-413-7139
email us here
Visit us on social media:
LinkedIn
Bluesky
Facebook
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
